- New data confirms use of intradermal delivery of eVLPs may be a potent “off-the-shelf” immunotherapy vaccine
- Poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 32nd Annual Meeting on Friday, November 10th
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (VBI) today announced that Catalina Soare, VBI’s head of preclinical development, will present new preclinical data demonstrating the potency of VBI-1901 as a therapeutic vaccine candidate against glioblastoma multiforme (GBM) at the 32nd annual meeting of the Society for Immunotherapy of Cancer in National Harbor, Maryland, on November 10, 2017.
Dr. Soare will present preclinical data, which confirms the use of intradermal delivery of VBI’s enveloped virus-like particle (eVLP), VBI-1901, may be a potent “off-the-shelf” dendritic cell vaccine. Following intradermal injection of VBI-1901, migratory dendritic cells at the injection site were confirmed to stimulate potent, adaptive T-cell immunity.
The FDA recently accepted VBI’s IND for VBI-1901. The company expects to initiate enrollment in a multi-center Phase 1/2a clinical study evaluating VBI-1901 in patients with recurrent GBM in the fourth quarter of 2017.
- Event: Annual Meeting of the Society for Immunotherapy of Cancer
- Date: Friday, November 10, 2017
- Time: 12:30 PM – 2:00 PM EST; 6:30 PM – 8:00 PM EST
- Location: Gaylord National Hotel & Convention Center, National Harbor, Maryland
- Event Website: http://www.sitcancer.org/education/annualmeeting
GBM Program Background
Glioblastoma is among the most common and aggressive malignant primary brain tumors in humans. In the U.S. alone, 12,000 new cases are diagnosed each year. The current standard of care for treating GBM is surgical resection, followed by radiation and chemotherapy. Even with aggressive treatment, GBM progresses rapidly and is exceptionally lethal, with median patient survival of less than 16 months.
Targeted immunotherapy may provide a promising adjunct or alternative to conventional GBM treatment. Immunotherapy is a fundamentally different way of treating cancer that stimulates the patient’s immune system to resume its attack on tumors. While conventional therapies are non-specific and may damage surrounding normal tissues, targeted immunotherapy may offer a highly specific and potentially long-lasting treatment approach that leverages the immune system to protect against cancer.
Developing a broadly applicable GBM immunotherapy requires the identification of antigens that are consistently expressed on GBM tumor cells. Recent research has demonstrated that an anti-CMV dendritic cell vaccination regimen may extend overall survival in patients with GBM. Thus, effective targeting of CMV antigens may represent an attractive strategy for a GBM immunotherapy.
To learn more about VBI’s GBM immunotherapy program, visit: https://www.vbivaccines.com/gbm/
VBI Vaccines Inc. (“VBI”) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI’s first marketed product is Sci-B-Vac™, a hepatitis B (HBV) vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vac is approved for use in Israel and 14 other countries. VBI’s eVLP Platform technology allows for the development of enveloped virus-like particle (eVLP) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus (CMV) and glioblastoma multiforme (GBM). VBI is also advancing its LPV™ Thermostability Platform, a proprietary formulation and process that enables vaccines and biologics to preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). These statements involve risks and uncertainties that could cause actual results to differ materially, including, but not limited to, the satisfaction of closing conditions, prevailing market conditions, the anticipated use of the proceeds of the offerings which could change as a result of market conditions or for other reasons, and the impact of general economic, industry or political conditions in the United States or internationally. Additional risks and uncertainties relating to the proposed offerings, VBI and its business can be found under the heading “Risk Factors” in the preliminary prospectus supplement and accompanying prospectus relating to the offerings, in VBI’s most recent quarterly and annual reports filed with the SEC and with the Canadian security regulatory authorities at www.sedar.com and in the preliminary prospectus supplement and accompanying prospectus relating to the offerings to be filed with the SEC. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. All such forward-looking statements made herein are based on our current expectations and we undertake no duty or obligation to update or revise any forward-looking statements for any reason, except as required by law.